CANCER DRUG DEVELOPMENT PIPELINE
Oncology Drug Pipeline & Cancer Clinical Trials
Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.
PF-07265028 | New project
Solid Tumors
HPK1 inhibitor
PF-07257876 | New project
NSCLC (Biologic)
CD47xPDL1 bispecific
PF-06647020 | New project
NSCLC (Biologic)
PTK7 targeted cytotoxicity
PF-07248144 + PF-07220060 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier + CDK4 inh
PF-07799544 | New project
Solid Tumors
MEK brain penetrant inhibitor
PF-07220060 + enzalutamide | New project
Prostate Cancer
CDK4 inhibitor
PF-07104091 | New project
Ovarian Cancer
CDK2 inhibitor
PF-07799933 BRAF Class 2 | New project
Cancer
BRAF Class 1 and Class 2 inhibitor
PF-07104091 + PF-07220060 | New project
Breast Cancer Metastatic
CDK2 + CDK4 inhibitors
PF-07260437 | New project
Breast Cancer Metastatic (Biologic)
B7H4-CD3 bispecific
PF-07284892 | New project
Cancer
SHP2 tyrosine phosphatase inhibitor
PF-07248144 | New project
Breast Cancer Metastatic
KAT6 epigenetic modifier
PF-07104091 | New project
Breast Cancer Metastatic
CDK2 inhibitor
PF-06940434 | New project
Solid Tumors (Biologic)
Integrin alpha-V/beta-8 antagonist
PF-07062119 | New project
Advanced/Metastatic Gastrointestinal Cancer (Biologic)
GUCY2c CD3 bispecific antibody
PF-07220060 | New project
Breast Cancer Metastatic
CDK4 inhibitor
PF-06821497 + enzalutamide | New project
Prostate Cancer
EZH2 inhibitor
maplirpacept (TTI-622) | New project
Hematological Malignancies (Biologic)
CD47-SIRPa fusion protein
vepdegestrant (ARV-471) | New project
ER+/HER2- Early Breast Cancer
ER-targeting PROTAC protein degrader
IBRANCE + vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer
CDK 4,6 kinase inhibitor ER-targeting PROTAC protein degrader
vepdegestrant (ARV-471) | New project
ER+/HER2- Metastatic Breast Cancer
ER-targeting PROTAC protein degrader
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Transplant-Ineligible (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (Biologic)
BCMA-CD3 bispecific antibody
ELREXFIO (elranatamab-bcmm) | New project
Multiple Myeloma Double-Class Exposed (Biologic)
BCMA-CD3 bispecific antibody
BRAFTOVI (encorafenib) + MEKTOVI (binimetinib)+ KEYTRUDA(pembrolizumab) | New project
BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma
BRAF kinase inhibitor andMEK inhibitor and anti-PD-1
BRAFTOVI (encorafenib) + ERBITUX (cetuximab) + chemotherapy | New project
1st line BRAF-mutant Metastatic Colorectal Cancer
BRAF kinase inhibitor and anti- EGFR
TALZENNA (talazoparib) | New project
Combo w/ XTANDI (enzalutamide) for DNA Damage Repair (DDR)-deficient Metastatic Castration Sensitive Prostate Cancer
PARP inhibitor
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project
Non-Muscle-Invasive Bladder Cancer (Biologic)
Anti-PD-1
IBRANCE (palbociclib) | New project
ER+/HER2+ Metastatic Breast Cancer(PATINA)
CDK 4,6 kinase inhibitor
XTANDI (enzalutamide) | Project advanced
Non-metastatic High-Risk Castration Sensitive Prostate Cancer (PRIORITY REVIEW - U.S.)
Androgen receptor inhibitor
- 00 Phase 1
- 00 Phase 2
- 00 Phase 3
- 00 Registration
- 00 Total